SEC Form 4 · accession 0001209191-15-054470
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Janney
Director · 10% Owner
Period of report
Jun 16, 2015
Accepted (ET)
Jun 17, 2015 · 9:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.29 | Jun 16, 2015 | A | 23,940 | A | — | Jun 16, 2025 | Common Stock | 23,940 | 23,940 | D |
| Stock Option (Right to Buy)F2 | $6.29 | Jun 16, 2015 | A | 12,450 | A | — | Jun 16, 2025 | Common Stock | 12,450 | 12,450 | D |
Explanation of responses
- F1Option shares vest in 12 quarterly installments measured from the vesting commencement date, July 18, 2014.
- F2Option shares fully vest on the earlier of (i) June 16, 2016 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting.